Literature DB >> 11810353

[Comparison of severity of chronic pain in patients differing in pain diagnosis: an analysis by means of the Mainz Pain Staging System].

M Hüppe1, V Matthiessen, M Lindig, S Preuss, T Meier, W Baumeier, K Gerlach, P Schmucker.   

Abstract

INTRODUCTION: Testing the validity of the Mainz Pain Staging System (MPSS) is often carried out by pain classification according to chronic stage. It is assumed that pain syndromes distribute equally over the chronic stages. This analysis was carried out to answer three questions: Do different pain syndromes vary in chronicity, do the four axes of the MPSS differ between pain syndromes, and are there any specific item responses with respect to a pain syndrome?
METHODS: 406 patients with different pain diagnoses were included in this analysis. Patients were chosen from the PAIN-Documentation-System of the pain outpatients' department of the Medical University of Luebeck. The pain score according to MPSS had been assessed, and a diagnosis attributed according to the Multidimensional Classification of Pain (MASK).
RESULTS: Pain diagnoses do differ in pain chronification. Patients with headache showing the lowest chronification, and patients with back pain describing the most severe chronification, formed the extreme patient groups. Further analysis using the axes of the MPSS demonstrate different sensitivity with respect to pain syndromes, i. e. intake of drugs being the least sensitive and aspects of time being the most sensitive axes. Statistical analysis using configural frequency analysis indicated a relation between pain syndromes and specific item responses.
CONCLUSION: Using pain stages of the MPSS as an experimental factor in studies of pain, it is imperative either to control pain syndromes or to confine to a single pain syndrome, to avoid confusion between pain syndromes and severity of pain chronification.

Entities:  

Mesh:

Year:  2001        PMID: 11810353     DOI: 10.1007/s004820170020

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  8 in total

1.  [Severity of chronic back pain. Assessment with the Mainz Pain Staging System].

Authors:  D Michalski; A Hinz
Journal:  Schmerz       Date:  2006-06       Impact factor: 1.107

2.  [Success of treatment in higher stages of pain chronification as well? An evaluation of the Mainz pain staging system based on the QUAST-analysis sample].

Authors:  M Hüppe; C Maier; H Gockel; M Zenz; J Frettlöh
Journal:  Schmerz       Date:  2011-02       Impact factor: 1.107

3.  [Theories and models of chronicity: on the way to a broader definition of chronic back pain].

Authors:  H Raspe; A Hüppe; C Matthis
Journal:  Schmerz       Date:  2003-10       Impact factor: 1.107

4.  [Staging of pain in patients with chronic low back pain in inpatient rehabilitation: validity of the Mainz Pain Staging System of pain chronification].

Authors:  P Hampel; M F Moergel
Journal:  Schmerz       Date:  2009-04       Impact factor: 1.107

5.  [Significance of health-related quality of life and religiosity for the acceptance of chronic pain].

Authors:  K Gerbershagen; M Trojan; J Kuhn; V Limmroth; H Bewermeyer
Journal:  Schmerz       Date:  2008-10       Impact factor: 1.107

6.  [Psychosocial factors in chronic low back pain in orthopaedic inpatient rehabilitation. An analysis using the axes of the Mainz Pain Staging System].

Authors:  L Tlach; P Hampel
Journal:  Schmerz       Date:  2009-10       Impact factor: 1.107

7.  Fibromyalgia with severe forms of progression in a multidisciplinary therapy setting with emphasis on hyperthermia therapy--a prospective controlled study.

Authors:  Tobias Romeyke; Hans Christoph Scheuer; Harald Stummer
Journal:  Clin Interv Aging       Date:  2014-12-19       Impact factor: 4.458

8.  Pain chronification and the important role of non-disease-specific symptoms in patients with systemic sclerosis.

Authors:  Petra Hoederath; Oliver Distler; Caroline Evers; Suzana Jordan; Britta Maurer; Mike Oliver Becker; Carina Mihai; Rucsandra Dobrota
Journal:  Arthritis Res Ther       Date:  2021-01-19       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.